The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 12th 2025
First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
gMG Imposes an Enormous Economic Burden on Patients
October 10th 2023Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).
Read More
Avidity Biosciences Gains FDA Orphan Drug Designation for Patients With DMD
October 9th 2023Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).
Read More
Lung Effects of Particulate Matter Exposure in WTC First Responders Still Redound Decades Later
October 9th 2023New research explores the risk factors for lung disease in firefighters who were exposed to particulate matter when responding to the attacks on the World Trade Center (WTC) on September 11, 2001, as well as interventions that may mediate inflammatory responses.
Read More
Experts Debate Terminology and Treatment of Asthma-COPD Overlap
October 9th 2023As evidenced by a debate at the CHEST Annual Meeting 2023, the pulmonology community disagrees on whether the overlap of asthma and chronic obstructive pulmonary disease (COPD) is a distinct entity and how best to treat it.
Read More
Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL
October 6th 2023Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.
Read More
FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer
October 6th 2023The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Read More
First Tocilizumab Biosimilar Approved in the United States
October 5th 2023The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Read More
Alcohol Use Not Associated With Lower Odds of Achieving SVR With Hepatitis C Treatment
October 4th 2023The researchers noted that their findings suggest clinicians and policy makers should encourage hepatitis C virus (HCV) treatment in those with unhealthy alcohol consumption or alcohol use disorder (AUD) rather than create barriers to it.
Read More